Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapySAISHO, Toshimitsu; OKUSAKA, Takuji; UENO, Hideki et al.Hepato-gastroenterology. 2005, Vol 52, Num 66, pp 1654-1658, issn 0172-6390, 5 p.Article

A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinomaIKEDA, Masafumi; OKUSAKA, Takuji; UENO, Hideki et al.Cancer. 2005, Vol 103, Num 4, pp 756-762, issn 0008-543X, 7 p.Article

Do Recurrent and Metastatic Pancreatic Cancer Patients Have the Same Outcomes with Gemcitabine Treatment?HASHIMOTO, Kenji; UENO, Hideki; IKEDA, Masafumi et al.Oncology. 2009, Vol 77, Num 3-4, pp 217-223, issn 0030-2414, 7 p.Article

A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancerUENO, Hideki; OKUSAKA, Takuji; IKEDA, Masafumi et al.Oncology. 2005, Vol 69, Num 5, pp 421-427, issn 0030-2414, 7 p.Article

A phase II trial of transcatheter arterial infusion chemotherapy with an epirubicin-Lipiodol emulsion for advanced hepatocellular carcinoma refractory to transcatheter arterial embolizationTANAKA, Tsutomu; IKEDA, Masafumi; OKUSAKA, Takuji et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 4, pp 683-688, issn 0344-5704, 6 p.Article

Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patientsMORIZANE, Chigusa; OKUSAKA, Takuji; ITO, Yoshinori et al.Oncology. 2005, Vol 68, Num 4-6, pp 432-437, issn 0030-2414, 6 p.Article

Population Pharmacokinetics of Gemcitabine and Its Metabolite in Japanese Cancer Patients: Impact of Genetic PolymorphismsSUGIYAMA, Emiko; KANIWA, Nahoko; YAMAMOTO, Noboru et al.Clinical pharmacokinetics. 2010, Vol 49, Num 8, pp 549-558, issn 0312-5963, 10 p.Article

Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinomaIKEDA, Masafumi; SHIINA, Shuichiro; ASAOKA, Yoshinari et al.Investigational new drugs. 2014, Vol 32, Num 5, pp 928-936, issn 0167-6997, 9 p.Article

Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patientsMORIZANE, Chigusa; OKUSAKA, Takuji; SUZUKI, Eiichiro et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 957-964, issn 0344-5704, 8 p.Article

A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinomaKANAI, Fumihiko; YOSHIDA, Haruhiko; MORIZANE, Chigusa et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 2, pp 315-324, issn 0344-5704, 10 p.Article

Treatment Efficacy/Safety and Prognostic Factors in Patients with Advanced Biliary Tract Cancer Receiving Gemcitabine Monotherapy: An Analysis of 100 CasesSUZUKI, Eiichiro; FURUSE, Junji; KOJIMA, Yasushi et al.Oncology. 2010, Vol 79, Num 1-2, pp 39-45, issn 0030-2414, 7 p.Article